The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Letter to the editor
Editor, – I wish to point out an error in 'Disease modifying drugs in adult rheumatoid arthritis' (Aust Prescr 2003;26:36-40). On page 38 the article says sulfasalazine contains acetylsalicylic acid and sulfapyridine. This should be 5-aminosalicylic acid and sulfapyridine.